UPDATES
Current Insurance Issues
Current Insurance Issues in the U.S.
The world of health insurance can be confusing. When advocating for healthcare reform, it is vital to understand the specific parts of the health insurance industry that are being affected by various legislation. What does it mean when a Federal bill impacts all commercial, private plans, while a State bill can impact all government, public plans?
Certain aspects of insurance are regulated by the federal government while others are controlled by the states. Federal legislation may provide more sweeping changes, but state legislation is necessary to fill in the “gaps” in coverage.
The resources on this page are meant to provide general information about the insurance industry, break down the different types of insurance, and define common terms in a way that will help you, as an advocate, be fully aware of the impact a bill can have.
RECENT DEVELOPMENTS
Nov 10/Steven Newmark
The outcome of another Affordable Care Act case going before the Supreme Court could have a big impact on people with pre-existing conditions. Here’s what to know.
Nov 13/GHLF Staff
More than half of patients are denied approval for proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), according to research published in the journal Circulation. And that’s true even though many appear to meet labeled indicators, th
Jul 19/GHLF Staff
GHLF recently worked with the University of Michigan’s Center for Value Based Insurance Design (V-BID) on a report about Copayment Assistance Programs.
The Data
U.S. Healthcare Spending
U.S. Healthcare Spending
The United States spends more on healthcare than any other nation in the world. This infographic illustrates how the healthcare spending pie is cut, and where the money goes.
VIDEOS
ARTICLES & PRESS RELEASES
Nov 10
The outcome of another Affordable Care Act case going before the Supreme Court could have a big impact on people with pre-existing conditions. Here’s what to know.
⇀ READ MOREMore than half of patients are denied approval for proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), according to research published in the journal Circulation. And that’s true even though many appear to meet labeled indicators, the data shows. “Although a combination of clinical characteristics increases the likelihood of approval, payer type is the most significant […]
⇀ READ MOREGHLF recently worked with the University of Michigan’s Center for Value Based Insurance Design (V-BID) on a report about Copayment Assistance Programs.
⇀ READ MORE